US Stock MarketDetailed Quotes
MGTX MeiraGTx Holdings
- 6.150
- +0.310+5.31%
Close Dec 20 16:00 ET
- 6.500
- +0.350+5.69%
Post 20:01 ET
480.64MMarket Cap-5.13P/E (TTM)
6.480High5.660Low1.20MVolume5.800Open5.840Pre Close7.38MTurnover3.98%Turnover RatioLossP/E (Static)78.15MShares7.60052wk High5.02P/B184.97MFloat Cap3.85052wk Low--Dividend TTM30.08MShs Float30.230Historical High--Div YieldTTM14.04%Amplitude3.490Historical Low6.162Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
MeiraGTx Holdings Stock Forum
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Aav2-Haqp1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX) announced five poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress in Rome, Italy. The posters highlight the company's advancements in genetic medicine and cell therapy platforms:
1. Optimized AAV manufacturing platform yielding high titers and improved product quality.
2....
MeiraGTx Holdings | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(8.6%),Johnson & Johnson Innovation-JJDC, Inc.(8.6%)
MeiraGTx Holdings PLC: Primary Study Objective of Safety and Tolerability Was Met
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi -4/sh
MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage genetic medicine company, has announced the pricing of an underwritten offering of 12,500,000 ordinary shares at $4.00 per share. The offering, expected to close on August 13, 2024, aims to raise $50 million in gross proceeds. Sanofi led the financing with a $30 million equity investment, joined by Perceptive Advisors and other inst...
No comment yet